blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3576748

EP3576748 - SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.02.2024
Database last updated on 20.05.2024
FormerThe patent has been granted
Status updated on  03.03.2023
FormerGrant of patent is intended
Status updated on  11.07.2022
FormerExamination is in progress
Status updated on  04.06.2021
FormerRequest for examination was made
Status updated on  08.11.2019
FormerThe international publication has been made
Status updated on  11.08.2018
Most recent event   Tooltip10.05.2024Lapse of the patent in a contracting state
New state(s): SI		published on 12.06.2024 [2024/24]
Applicant(s)For all designated states
Vanderbilt University
305 Kirkland Hall
2201 West End Avenue
Nashville, TN 37240 / US
[2019/50]
Inventor(s)01 / CHERRINGTON, Alan
8012 East Chase Court
Nashville TN 37221-4129 / US
02 / MAGGS, David
6 Joy Street Apt. 2
Boston MA 02108 / US
03 / GHOSH, Soumitra
12334 Pathos Lane
San Diego CA 92129 / US
04 / RHODES, Christopher, A.
12868 Baywind Point
San Diego CA 92130 / US
05 / LIN, Jui-chen
8875 Costa Verde Blvd. Apt 1603
San Diego CA 92122 / US
 [2019/50]
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[2023/14]
Former [2019/50]Chapman, Paul Gilmour
Marks & Clerk LLP
40 Torphichen Street
Edinburgh EH3 8JB / GB
Application number, filing date18747931.602.02.2018
[2019/50]
WO2018US16647
Priority number, dateUS201762454613P03.02.2017         Original published format: US 201762454613 P
[2019/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018144867
Date:09.08.2018
Language:EN
[2018/32]
Type: A1 Application with search report 
No.:EP3576748
Date:11.12.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 09.08.2018 takes the place of the publication of the European patent application.
[2019/50]
Type: B1 Patent specification 
No.:EP3576748
Date:05.04.2023
Language:EN
[2023/14]
Search report(s)International search report - published on:US09.08.2018
(Supplementary) European search report - dispatched on:EP06.10.2020
ClassificationIPC:A61K31/702, A61K45/06, C12N15/16, C12N15/17, G01N33/50, A61K38/26, A61K38/28, A61K47/10, A61K47/20, A61K47/32, A61P3/10
[2020/45]
CPC:
A61K45/06 (EP); A61K38/28 (EP,US); A61K38/26 (EP,US);
A61K47/10 (EP,US); A61K47/20 (EP,US); A61K47/32 (EP,US);
A61K9/0019 (EP,US); A61P3/10 (EP,US); A61K2300/00 (EP) (-)
C-Set:
A61K2300/00, A61K38/26 (EP);
A61K2300/00, A61K38/28 (EP)
Former IPC [2019/50]A61K31/702, A61K45/06, C12N15/16, C12N15/17, G01N33/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/50]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:SYSTEME, ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON DIABETES[2019/50]
English:SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES[2019/50]
French:SYSTÈME, COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DU DIABÈTE[2019/50]
Entry into regional phase28.08.2019National basic fee paid 
28.08.2019Search fee paid 
28.08.2019Designation fee(s) paid 
28.08.2019Examination fee paid 
Examination procedure28.08.2019Examination requested  [2019/50]
30.04.2021Amendment by applicant (claims and/or description)
07.06.2021Despatch of a communication from the examining division (Time limit: M04)
15.10.2021Reply to a communication from the examining division
04.02.2022Despatch of a communication from the examining division (Time limit: M04)
14.06.2022Reply to a communication from the examining division
12.07.2022Communication of intention to grant the patent
13.12.2022Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
21.02.2023Fee for grant paid
21.02.2023Fee for publishing/printing paid
21.02.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23166369.1  / EP4233876
Opposition(s)08.01.2024No opposition filed within time limit [2024/11]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
21.02.2023Request for further processing filed
21.02.2023Full payment received (date of receipt of payment)
Request granted
01.03.2023Decision despatched
Fees paidRenewal fee
27.02.2020Renewal fee patent year 03
25.02.2021Renewal fee patent year 04
25.02.2022Renewal fee patent year 05
27.02.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL05.04.2023
AT05.04.2023
CZ05.04.2023
DK05.04.2023
EE05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RO05.04.2023
RS05.04.2023
SE05.04.2023
SI05.04.2023
SK05.04.2023
SM05.04.2023
NO05.07.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
[2024/24]
Former [2024/10]AL05.04.2023
AT05.04.2023
CZ05.04.2023
DK05.04.2023
EE05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RO05.04.2023
RS05.04.2023
SE05.04.2023
SK05.04.2023
SM05.04.2023
NO05.07.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/08]AL05.04.2023
AT05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
SE05.04.2023
SK05.04.2023
SM05.04.2023
NO05.07.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/03]AL05.04.2023
AT05.04.2023
FI05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
SE05.04.2023
NO05.07.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2024/01]AL05.04.2023
AT05.04.2023
HR05.04.2023
LT05.04.2023
LV05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
SE05.04.2023
NO05.07.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2023/51]AL05.04.2023
AT05.04.2023
HR05.04.2023
NL05.04.2023
PL05.04.2023
RS05.04.2023
SE05.04.2023
NO05.07.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2023/50]AL05.04.2023
AT05.04.2023
NL05.04.2023
PL05.04.2023
SE05.04.2023
NO05.07.2023
GR06.07.2023
IS05.08.2023
PT07.08.2023
Former [2023/48]AT05.04.2023
NL05.04.2023
SE05.04.2023
NO05.07.2023
PT07.08.2023
Former [2023/46]NL05.04.2023
PT07.08.2023
Former [2023/43]NL05.04.2023
Documents cited:Search[XY]WO2004060387  (DIOBEX INC [US], et al) [X] 1-7,9,11-15 * the whole document * [Y] 1-15;
 [XY]WO2006004696  (DIOBEX INC [US], et al) [X] 1-7,9,11-15 * the whole document * [Y] 1-15;
 [XY]  - STEPHEN CL GOUGH ET AL, "Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes", EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, GB, (20151118), vol. 11, no. 1, doi:10.1586/17446651.2016.1113129, ISSN 1744-6651, pages 7 - 19, XP055698799 [X] 1,3,6,9,11,12 * the whole document * [Y] 1-15

DOI:   http://dx.doi.org/10.1586/17446651.2016.1113129
 [YP]  - DAVID JULIA ET AL, "When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?", JOURNAL OF DIABETES AND ITS COMPLICATIONS, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 33, no. 12, doi:10.1016/J.JDIACOMP.2019.107473, ISSN 1056-8727, (20191022), (20191022), XP085919687 [YP] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jdiacomp.2019.107473
International search[A]US5321008  (BEAUMONT KEVIN [US], et al) [A] 1-33 * ; entire document *;
 [XY]US2006014670  (GREEN DANIEL T [US], et al) [X] 1-6, 12-13, 15-17, 21-22, 25-30 * ; abstract; paragraphs [0006]-[0009], [0016], [0026], [0033], [0036], [0064]-[0065], [0091] * [Y] 7-11, 14, 18-20, 23-24, 31-33;
 [A]US2009124559  (BACHOVCHIN WILLIAM W [US], et al) [A] 1-33* ; entire document *;
 [Y]US2012232001  (PRESTRELSKI STEVEN [US], et al) [Y] 7-11, 23-24, 31-33 * ; paragraphs [0087], [0104]-[0105], [0111]-[0112] *;
 [A]US2016022899  (ALJOHANI KAMAL AHMED [US]) [A] 1-33 * ; entire document *;
 [Y]  - Anonymous, (20160325), pages 1 - 26, NCBI, URL: https://www.ncbi.nlm.nih.gov/books/NBK30, XP055619449 [Y] 1-33 * ; page 9, paragraph 4; page 10, paragraph 2 *
 [Y]  - EDGERTON, DS et al., "Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog", Diabetes, (20140000), vol. 63, pages 3950 - 3954, XP055530989 [Y] 14 * , paragraphs 1-2 *

DOI:   http://dx.doi.org/10.2337/db14-0266
 [Y]  - CHERRINGTON, AD et al., "The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog", The Journal of clinical investigation, (19760000), vol. 58, no. 6, pages 1407 - 1418, XP055530997 [Y] 18-20 * ; *

DOI:   http://dx.doi.org/10.1172/JCI108596
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.